Authors : Dr. Sweta Gulati; Seema Shukla; Pranshi Jain; Shikha Modi; Vandana Chugh

Volume/Issue : Volume 11 - 2026, Issue 3 - March

Google Scholar : https://tinyurl.com/bde82w4b

Scribd : https://tinyurl.com/4fwatfkd

DOI : https://doi.org/10.38124/ijisrt/26mar2090

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background The Coronavirus disease 2019 (COVID -19) pandemic caused by severe acute respiratory syndrome, Corona virus 2(SARS-CoV-2) infection has affected millions of patients worldwide[1]. As we all know its impact is more alarming in patients with co morbidities like Hypertension, CAD, DM, Asthma, or many respiratory illnesses etc[2,3,4,5]. So, one should consider effective therapeutic approach from already existing drugs as a more efficient way to save lives. Statin group of drugs are well known lipid lowering agents and their well known pleiotropic effects are helpful in reducing mortality and length of stay in hospital with various respiratory infections, this triggered us to evaluate its usefulness in COVID-19 patients. So, our primary aim is to see reduction in mortality and thereby length of stay in hospitalised patients (statin users); which is our secondary aim of the study.  Results After initial recruitment of 300 patients with COVID-19 and careful consideration of the exclusion criteria a total of 150 patients were actually studied, out of which 75 patients received statins, and hence were included in our retrospective study. Out of 75 patients 54 (72%) patients survived, who took atorvastatin and 47 patients (62%) survived in statin users. Odds Ratio is 1.53 (chance of survival are higherby 1.53 times in cases where Atorvastatin is given v/s where Atorvastatin is not given). Also, duration of stay in Atorvastatin users group patients is significant i.e. P value is <0.05 (significant).  Conclusions Although we could not demonstrate a significant association between statin users and a reduction in mortality in patients with COVID 19 which was our primary outcome. We strongly recommend that to reach on the point of clinical significance one should study large number of population retrospectively. It can be a cheap and effective pharmacotherapy which is easily available and used by many patients. And who knows when next pandemic knocks the door of world as many variants are reportedly coming these days, hence we should be prepared with our easily available preventive armamentarium.

References :

1. World Health Organization. WHO coronavirus disease (COVID‐19) dashboard. 2021. https://covid19.who.int/. Accessed January 20 2021
2. Bae S, Kim SR, Kim M‐N, Shim WJ, Park S‐MJH. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID‐19 according to age: a systematic review and meta‐analysis. Heart. 2021;107(5):373–380. 10.1136/heartjnl-2020-317901 [DOI] [PubMed] [Google Scholar]
3. Fang CH, Li JJ, Hui RT. Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses. 2005;64(1):192‐196. 10.1016/j.mehy.2004.06.018 [DOI] [PubMed] [Google Scholar]
4. Diaz Arocutipa C, Melgar Talavera B, Alvarado Yarasca Á. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients. International Journal of Infectious Diseases, 2021; 110, 374-381
5. Zheng Y‐Y, Ma Y‐T, Zhang J‐Y, Xie X. COVID‐19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259‐260. 10.1038/s41569-020-0360-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
6. Becker RC. COVID‐19‐associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020;50(3):499‐511. 10.1007/s11239-020-02230-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Novack V, Eisinger M, Frenkel A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double‐blind placebo controlled clinical trial. Intensive Care Med. 2009;35(7):1255‐1260. 10.1007/s00134-009-1429-0 [DOI] [PubMed] [Google Scholar]
8. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30‐day mortality for patients hospitalized with community‐acquired pneumonia. Respir Res. 2005;6(1):82. 10.1186/1465-9921-6-82 [DOI] [PMC free article] [PubMed] [Google Scholar]